Diagnosis & Disease Information

ASH: Pomalidomide + Low-Dose Dexamethasone Improves PFS, OS in Relapsed/Refractory Multiple Myeloma

Pomalidomide plus low-dose dexamethasone significantly improved progression-free survival (PFS) and overall survival (OS) in patients with relapsed/refractory multiple myeloma vs high-dose dexamethasone alone and “should be considered as a new treatment option for these patients” who have exhausted lenalidomide and bortezomib, a study presented during the 54th American Society of Hematology Annual Meeting and Exposition recommended.

Next post in Hematologic Cancers